Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that is highly radiosensitive and immunogenic. Immunotherapy is the primary treatment of advanced disease, and immune checkpoint inhibitors show promise as neoadjuvant or adjuvant therapy in patients with high-risk resectable MCC. Emerging biomarkers of tumor burden are becoming increasingly important in identifying high-risk patients and in post-treatment surveillance. Further research is needed to determine the optimal duration of anti-PD-(L)1 treatment and second-line options for patients with MCC refractory to immunotherapy. This review covers the characteristics and management of MCC including recent innovations and areas of active investigation. Published by Elsevier Inc.

Citation

Jennifer Strong, Patrick Hallaert, Isaac Brownell. Merkel Cell Carcinoma. Hematology/oncology clinics of North America. 2024 Oct;38(5):1133-1147

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 39060119

View Full Text